Compare McDonald's Corp (MCD) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs Organon & Co. Common Stock — how do they compare? McDonald's Corp trades at $240 (market cap $166.87B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: McDonald's Corp is far larger — about 46.1× Organon & Co. Common Stock's market cap, and McDonald's Corp pays the higher dividend (3.27%). Which is the better fit depends on your goals — on Pluang, investors hold McDonald's Corp for 165 Days and Organon & Co. Common Stock for 0 Days on average.
| MCD | OGN | |
|---|---|---|
Market Cap | $166.87B | $3.62B |
Volume | 4,543,119 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $13.81 |
52-Week Low | $230.88 | $5.70 |
Typical Hold Time | 165 Days | 0 Days |
Enterprise Value | $220.64B | $11.04B |
Dividend Yield | 3.27% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $235.81, up 0.07% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.38 exceeding the $3.32 estimate. Revenue growth is steady, reaching $26.89B in 2025, while net income margin remains robust at 31.72%. Recent news highlights the launch of the 'McDonald's NEXT' strategy focusing on automation and menu innovation to drive growth.
The outlook is supported by analyst optimism with a consensus price target of $284.70, implying significant upside. However, risks include inflationary pressures on franchisee margins and high long-term debt of $38.42B. The stock presents a value opportunity with a P/E of 19.16, but investors should weigh execution risks against growth initiatives.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
